OIPE FOR SUN 2 6 2006 G

POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM

	710/35/81 (04-0)
Application Number	10/559,405
Filing Date	12/5/05
First Named Inventor	John W. Patterson
Title	AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
Art Unit	
Examiner Name	
	· · · · · · · · · · · · · · · · · · ·

IND	ICATION FORM	Art Unit	<u> </u>			
		Examin	er Name	}		
		Attorne	y Docket Number	015058-00	)5010US	
I hereby revoke all previous powers of attorney given in the above-identified application.						
I hereby appoint:						
Practitioners Number:	Practitioners associated with the Customer		20350			
OR						
Practitioner(s	s) named below:					
	Name		Registration Number			
			<del></del>			
		<del></del>				
as my/our attorney(s) Trademark Office con	or agent(s) to prosecute the application	n identified ab	ove, and to transact all	business in the	he United States Patent	and
K=21	change the correspondence address for s associated with the above-mentioned		* *	0:		
Ine address	3 associated with the above-mentioned	1 Customer N	iumber.			
OR						
The address	s associated with Customer Number:			l		
OR						
Firm or Individual Nar	me					
Address						
,	·					
City			State		Zip	
Country			· · · · · · · · · · · · · · · · · · ·	, <b>L</b>		
Telephone			Email			
I am the:						
Applicant/Inve	ntor.					
Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
SIGNATURE of Applicant or Assignee of Record						
Signature Wayse Montgonery Date 6/21/06						
Name WAYNE MONTEOMERY Telephone 650 866636						
Title and Company ASSISTANT SECRETARY Applera CARPORATION					7N	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.					ne	
*Total of forms are submitted.						

60797361 v1



PTO/SB/96 (04-03)
Attorney Docket No. 015058-005010US

## MDER 37 CFR 3.73(b) Applicant/Patent Owner: John W. Patterson and Soon H. Woo Filed/Issue Date: 12/05/05 Application Serial No: 10/559,405 Entitled: AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS , a Corporation (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.) (Name of Assignee) states that it is: the assignee of record of the entire right, title, and interest; or an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is % in the patent application/patent identified above by virtue of either: A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached. B. A chain of title from the originally named inventor(s), of the patent application/patent identified above, to the current assignee as shown below: To: 1. From: , The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached. 2. From: To: The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached. 3. From: \_ To: The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. ☐ Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Attorney Docket No.: 015058-005010US Client Ref. No.: CL001471 PCT-US



## DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of	AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS					
Invention						
As the below	w named inventor(s), I/we declare that:					
This declara	ation is directed to:	:				
	The attached application, or					
	Application No. 10/559,405 , filed on December 5, 2005 , Int'l Application No.: PCT/US04/17654 International Filing Date: June 4, 2004					
	as amended on	(if applicable);				
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;						
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;						
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.						
	WARNING:					
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.						
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.						
FULL NAN	ME OF INVENTOR(S)					
		Citizen of: United States				
Signature:		Date: June 8, 2006				
Inventor tv	vo: Soon H. Woo	Citizen of: Canada				
Signature:		Date:				
Additio	onal inventors or a legal representative are being named on	additional form(s) attached hereto.				

Attorney Docket No.: 015058-005010US Client Ref. No.: CL001471 PCT-US

PTO/SB/01A 10-05)

## DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of	AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS			
Invention				
	<u> </u>			
As the below	v named inventor(s), I/we declare that:			
This declara	tion is directed to:	·		
	The attached application, or			
	Application No. 10/559,405, filed of Int'l Application No.: PCT/US04/17654 Internation			
	as amended on	(if applicable);		
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;				
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;				
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
	WARNING:			
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.				
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
FULL NAM	IE OF INVENTOR(S)			
Inventor or	ne: John W. Patterson	Citizen of: United States		
Signature:		Date:		
Inventor tw	ro: Sogn H. Woo	Citizen of: Canada		
Signature:	Soontwoo	Date: May 27, 2006		
Additio	nal inventors or a legal representative are being named on	additional form(s) attached hereto.		